Insider Trades134 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 5,396 | $3.15 | $1.6B | -58.98% | +6.32% | $17.0K | -0.49% | — | Trim |
| Jun 5, 2026 | Sell | RXRX | Najat Khan | CEO and President | 23,588 | $3.58 | $1.6B | -58.98% | +6.32% | $84.5K | -1.07% | 10b5-1 | Trim |
| May 15, 2026 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 25,018 | $3.04 | $1.6B | -58.98% | +6.32% | $76.1K | -2.21% | — | Trim |
| May 15, 2026 | Sell | RXRX | David Hallett | Chief Scientific Officer | 26,657 | $3.04 | $1.6B | -58.98% | +6.32% | $81.0K | -2.43% | — | Trim |
| May 15, 2026 | Sell | RXRX | Najat Khan | CEO and President | 62,701 | $3.04 | $1.6B | -58.98% | +6.32% | $190.6K | -2.77% | — | Trim |
| Apr 6, 2026 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 48,028 | $3.11 | $1.6B | -58.98% | +6.32% | $149.4K | -4.07% | — | Trim |
| Mar 16, 2026 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 15,031 | $3.40 | $1.6B | -58.98% | +6.32% | $51.2K | -0.63% | 10b5-1 | Trim |
| Mar 9, 2026 | Sell | RXRX | Najat Khan | CEO and President | 28,298 | $3.35 | $1.6B | -58.98% | +6.32% | $94.7K | -1.24% | 10b5-1 | Trim |
| Feb 17, 2026 | Sell | RXRX | David Hallett | Chief Scientific Officer | 11,908 | $3.49 | $1.6B | -58.98% | +6.32% | $41.6K | -1.07% | — | Trim |
| Feb 17, 2026 | Sell | RXRX | Najat Khan | CEO and President | 14,280 | $3.49 | $1.6B | -58.98% | +6.32% | $49.8K | -0.62% | — | Trim |
| Feb 17, 2026 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 25,334 | $3.27 | $1.6B | -58.98% | +6.32% | $82.9K | -1.04% | 10b5-1 | Trim |
| Feb 6, 2026 | Sell | RXRX | Najat Khan | CEO and President | 10,364 | $3.98 | $1.6B | -58.98% | +6.32% | $41.2K | -0.45% | — | Trim |
| Feb 6, 2026 | Sell | RXRX | David Hallett | Chief Scientific Officer | 11,400 | $3.98 | $1.6B | -58.98% | +6.32% | $45.4K | -1.02% | — | Trim |
| Feb 6, 2026 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 11,400 | $3.98 | $1.6B | -58.98% | +6.32% | $45.4K | -0.93% | — | Trim |
| Dec 29, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 21,383 | $4.18 | $1.6B | -58.98% | +6.32% | $89.4K | -2.73% | 10b5-1 | Trim |
| Dec 22, 2025 | Sell | RXRX | Najat Khan | Chief R&D Commercial Officer | 124,403 | $4.41 | $1.6B | -58.98% | +6.32% | $548.6K | -5.36% | 10b5-1 | Trim |
| Dec 19, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 40,000 | $4.50 | $1.6B | -58.98% | +6.32% | $180.0K | -0.80% | 10b5-1 | Trim |
| Dec 15, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 7,057 | $4.33 | $1.6B | -58.98% | +6.32% | $30.6K | -0.89% | — | Trim |
| Dec 4, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 60,000 | $3.09 | $1.6B | -58.98% | +6.32% | $185.2K | -1.01% | 10b5-1 | Trim |
| Nov 25, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 2,271 | $4.03 | $1.6B | -58.98% | +6.32% | $9.2K | -0.29% | — | Trim |
| Nov 17, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 11,908 | $4.14 | $1.6B | -58.98% | +6.32% | $49.3K | -1.48% | — | Trim |
| Nov 17, 2025 | Sell | RXRX | Najat Khan | Chief R&D Commercial Officer | 17,584 | $4.14 | $1.6B | -58.98% | +6.32% | $72.8K | -2.33% | — | Trim |
| Nov 17, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 80,390 | $4.15 | $1.6B | -58.98% | +6.32% | $333.6K | -1.35% | 10b5-1 | Trim |
| Nov 4, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 60,000 | $3.47 | $1.6B | -58.98% | +6.32% | $208.4K | -0.99% | 10b5-1 | Trim |
| Oct 23, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 100,000 | $5.70 | $1.6B | -58.98% | +6.32% | $570.0K | -1.96% | 10b5-1 | Trim |
| Oct 10, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 120,000 | $5.03 | $1.6B | -58.98% | +6.32% | $604.0K | -1.97% | 10b5-1 | Trim |
| Sep 25, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 100,000 | $4.76 | $1.6B | -58.98% | +6.32% | $476.0K | -1.96% | 10b5-1 | Trim |
| Sep 15, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 7,057 | $4.83 | $1.6B | -58.98% | +6.32% | $34.1K | -0.87% | — | Trim |
| Sep 10, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 120,000 | $3.92 | $1.6B | -58.98% | +6.32% | $471.0K | -1.97% | 10b5-1 | Trim |
| Aug 26, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 100,000 | $4.84 | $1.6B | -58.98% | +6.32% | $484.0K | -1.96% | 10b5-1 | Trim |
| Aug 15, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 11,908 | $5.64 | $1.6B | -58.98% | +6.32% | $67.2K | -1.45% | — | Trim |
| Aug 15, 2025 | Sell | RXRX | Najat Khan | Chief R&D Commercial Officer | 40,388 | $5.53 | $1.6B | -58.98% | +6.32% | $223.5K | -2.86% | — | Trim |
| Aug 15, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 40,390 | $5.64 | $1.6B | -58.98% | +6.32% | $227.8K | -4.06% | — | Trim |
| Aug 11, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 628,175 | $5.20 | $1.6B | -58.98% | +6.32% | $3.3M | -10.08% | 10b5-1 | Trim |
| Jun 16, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 7,057 | $4.92 | $1.6B | -58.98% | +6.32% | $34.7K | -0.34% | — | Trim |
| May 15, 2025 | Sell | RXRX | Najat Khan | Chief R&D Commercial Officer | 3,796 | $4.25 | $1.6B | -58.98% | +6.32% | $16.1K | -0.18% | — | Trim |
| May 15, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 11,908 | $4.25 | $1.6B | -58.98% | +6.32% | $50.6K | -0.56% | — | Trim |
| May 15, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 36,197 | $4.25 | $1.6B | -58.98% | +6.32% | $153.8K | -0.32% | — | Trim |
| Apr 1, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 26,571 | $5.09 | $1.6B | -58.98% | +6.32% | $135.4K | -1.24% | — | Trim |
| Mar 27, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 138,574 | $6.04 | $1.6B | -58.98% | +6.32% | $837.0K | -1.22% | 10b5-1 | Trim |
| Mar 17, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 7,057 | $6.84 | $1.6B | -58.98% | +6.32% | $48.3K | -0.33% | — | Trim |
| Mar 5, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 40,000 | $6.47 | $1.6B | -58.98% | +6.32% | $259.0K | -0.60% | 10b5-1 | Trim |
| Feb 18, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 10,879 | $10.64 | $1.6B | -58.98% | +6.32% | $115.8K | -0.50% | — | Trim |
| Feb 18, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 17,132 | $10.64 | $1.6B | -58.98% | +6.32% | $182.3K | -0.15% | — | Trim |
| Feb 5, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 40,000 | $7.90 | $1.6B | -58.98% | +6.32% | $316.0K | -0.59% | 10b5-1 | Trim |
| Feb 3, 2025 | Sell | RXRX | Najat Khan | Chief R&D Commercial Officer | 2,753 | $7.25 | $1.6B | -58.98% | +6.32% | $20.0K | -0.16% | — | Trim |
| Feb 3, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 5,569 | $7.25 | $1.6B | -58.98% | +6.32% | $40.4K | -0.06% | — | Trim |
| Feb 3, 2025 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 6,544 | $7.25 | $1.6B | -58.98% | +6.32% | $47.4K | -0.31% | — | Trim |
| Jan 8, 2025 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 40,000 | $7.18 | $1.6B | -58.98% | +6.32% | $287.2K | -0.87% | 10b5-1 | Trim |
| Dec 16, 2024 | Sell | RXRX | Ben R Taylor | Chief Financial Officer | 22,725 | $6.32 | $1.6B | -58.98% | +6.32% | $143.7K | -2.32% | — | Trim |
| Dec 4, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 40,000 | $7.14 | $1.6B | -58.98% | +6.32% | $285.6K | -0.87% | 10b5-1 | Trim |
| Nov 15, 2024 | Sell | RXRX | David J Mauro | Chief Medical Officer | 4,187 | $6.17 | $1.6B | -58.98% | +6.32% | $25.9K | -0.59% | — | Trim |
| Nov 15, 2024 | Sell | RXRX | Michael Secora | Chief Financial Officer | 11,937 | $6.17 | $1.6B | -58.98% | +6.32% | $73.7K | -0.35% | — | Trim |
| Nov 15, 2024 | Sell | RXRX | Tina Marriott | President and COO | 14,286 | $6.17 | $1.6B | -58.98% | +6.32% | $88.2K | -0.66% | — | Trim |
| Nov 15, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 26,023 | $6.17 | $1.6B | -58.98% | +6.32% | $160.7K | -0.26% | — | Trim |
| Nov 13, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 40,000 | $7.54 | $1.6B | -58.98% | +6.32% | $301.8K | -0.86% | 10b5-1 | Trim |
| Nov 12, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 108,750 | $3.72 | $1.6B | -58.98% | +6.32% | $404.3K | +0.65% | 10b5-1 | Trim |
| Oct 24, 2024 | Sell | RXRX | Tina Marriott | President and COO | 12,000 | $3.68 | $1.6B | -58.98% | +6.32% | $44.2K | +0.00% | 10b5-1 | Trim |
| Oct 8, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 108,750 | $3.36 | $1.6B | -58.98% | +6.32% | $365.0K | +0.67% | 10b5-1 | Trim |
| Oct 2, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 40,000 | $6.12 | $1.6B | -58.98% | +6.32% | $244.8K | -0.86% | 10b5-1 | Trim |
| Sep 26, 2024 | Sell | RXRX | Tina Marriott | President and COO | 12,000 | $4.03 | $1.6B | -58.98% | +6.32% | $48.4K | +0.00% | 10b5-1 | Trim |
| Sep 10, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 108,750 | $3.33 | $1.6B | -58.98% | +6.32% | $362.1K | +0.69% | 10b5-1 | Trim |
| Sep 4, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 40,000 | $6.09 | $1.6B | -58.98% | +6.32% | $243.6K | -0.86% | 10b5-1 | Trim |
| Aug 30, 2024 | Buy | RXRX | Christopher Gibson | Chief Executive Officer | 5,000 | $2.48 | $1.6B | -58.98% | +6.32% | $12.4K | +0.05% | — | Trim |
| Aug 29, 2024 | Buy | RXRX | Christopher Gibson | Chief Executive Officer | 5,000 | $2.48 | $1.6B | -58.98% | +6.32% | $12.4K | +0.05% | — | Trim |
| Aug 29, 2024 | Sell | RXRX | Tina Marriott | President and COO | 12,000 | $4.31 | $1.6B | -58.98% | +6.32% | $51.7K | +0.00% | 10b5-1 | Trim |
| Aug 28, 2024 | Buy | RXRX | Christopher Gibson | Chief Executive Officer | 5,000 | $2.48 | $1.6B | -58.98% | +6.32% | $12.4K | +0.05% | — | Trim |
| Aug 27, 2024 | Buy | RXRX | Christopher Gibson | Chief Executive Officer | 5,000 | $2.48 | $1.6B | -58.98% | +6.32% | $12.4K | +0.05% | — | Trim |
| Aug 26, 2024 | Buy | RXRX | Christopher Gibson | Chief Executive Officer | 5,000 | $2.48 | $1.6B | -58.98% | +6.32% | $12.4K | +0.05% | — | Trim |
| Aug 23, 2024 | Buy | RXRX | Christopher Gibson | Chief Executive Officer | 5,000 | $2.48 | $1.6B | -58.98% | +6.32% | $12.4K | +0.05% | — | Trim |
| Aug 15, 2024 | Sell | RXRX | Michael Secora | Chief Financial Officer | 11,962 | $6.69 | $1.6B | -58.98% | +6.32% | $80.0K | -0.34% | — | Trim |
| Aug 15, 2024 | Sell | RXRX | David J Mauro | Chief Medical Officer | 14,146 | $6.69 | $1.6B | -58.98% | +6.32% | $94.6K | -1.95% | — | Trim |
| Aug 15, 2024 | Sell | RXRX | Tina Marriott | President and COO | 14,319 | $6.69 | $1.6B | -58.98% | +6.32% | $95.8K | -0.65% | — | Trim |
| Aug 15, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 26,082 | $6.69 | $1.6B | -58.98% | +6.32% | $174.5K | -0.26% | — | Trim |
| Aug 13, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 108,750 | $3.36 | $1.6B | -58.98% | +6.32% | $365.3K | +0.70% | 10b5-1 | Trim |
| Aug 7, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 50,000 | $6.86 | $1.6B | -58.98% | +6.32% | $343.0K | -1.06% | 10b5-1 | Trim |
| Jul 25, 2024 | Sell | RXRX | Tina Marriott | President and COO | 12,000 | $4.60 | $1.6B | -58.98% | +6.32% | $55.2K | +0.00% | 10b5-1 | Trim |
| Jul 10, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 125,000 | $5.98 | $1.6B | -58.98% | +6.32% | $747.5K | -2.26% | 10b5-1 | Trim |
| Jul 9, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 108,750 | $3.62 | $1.6B | -58.98% | +6.32% | $393.2K | +0.72% | 10b5-1 | Trim |
| Jun 27, 2024 | Sell | RXRX | Tina Marriott | President and COO | 12,000 | $4.14 | $1.6B | -58.98% | +6.32% | $49.6K | +0.00% | 10b5-1 | Trim |
| Jun 13, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 108,750 | $4.17 | $1.6B | -58.98% | +6.32% | $453.7K | +0.74% | 10b5-1 | Trim |
| Jun 5, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 125,000 | $6.97 | $1.6B | -58.98% | +6.32% | $871.0K | -2.26% | 10b5-1 | Trim |
| May 30, 2024 | Sell | RXRX | Tina Marriott | President and COO | 6,000 | $4.92 | $1.6B | -58.98% | +6.32% | $29.5K | +0.00% | 10b5-1 | Trim |
| May 15, 2024 | Sell | RXRX | David J Mauro | Chief Medical Officer | 867 | $10.01 | $1.6B | -58.98% | +6.32% | $8.7K | -0.12% | — | Trim |
| May 15, 2024 | Sell | RXRX | Tina Marriott | President and COO | 9,998 | $10.01 | $1.6B | -58.98% | +6.32% | $100.1K | -0.45% | — | Trim |
| May 15, 2024 | Sell | RXRX | Michael Secora | Chief Financial Officer | 11,962 | $10.01 | $1.6B | -58.98% | +6.32% | $119.7K | -0.33% | — | Trim |
| May 15, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 26,082 | $10.01 | $1.6B | -58.98% | +6.32% | $261.1K | -0.25% | — | Trim |
| May 1, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 125,000 | $6.48 | $1.6B | -58.98% | +6.32% | $810.0K | -1.86% | 10b5-1 | Trim |
| Apr 25, 2024 | Sell | RXRX | Tina Marriott | President and COO | 6,000 | $4.37 | $1.6B | -58.98% | +6.32% | $26.2K | +0.00% | 10b5-1 | Trim |
| Apr 16, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 123,124 | $4.33 | $1.6B | -58.98% | +6.32% | $533.5K | +0.42% | 10b5-1 | Trim |
| Apr 3, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 155,000 | $7.49 | $1.6B | -58.98% | +6.32% | $1.2M | -2.73% | 10b5-1 | Trim |
| Mar 28, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 90,000 | $7.29 | $1.6B | -58.98% | +6.32% | $656.5K | -1.69% | 10b5-1 | Trim |
| Mar 21, 2024 | Sell | RXRX | Tina Marriott | President and COO | 16,000 | $5.90 | $1.6B | -58.98% | +6.32% | $94.5K | +0.00% | 10b5-1 | Trim |
| Mar 12, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 125,000 | $5.63 | $1.6B | -58.98% | +6.32% | $703.7K | +0.39% | 10b5-1 | Trim |
| Mar 6, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 111,243 | $8.05 | $1.6B | -58.98% | +6.32% | $895.9K | -0.52% | 10b5-1 | Trim |
| Feb 22, 2024 | Sell | RXRX | Tina Marriott | President and COO | 16,000 | $7.98 | $1.6B | -58.98% | +6.32% | $127.6K | +0.00% | 10b5-1 | Trim |
| Feb 15, 2024 | Sell | RXRX | Tina Marriott | President and COO | 5,379 | $12.43 | $1.6B | -58.98% | +6.32% | $66.9K | -0.83% | — | Trim |
| Feb 15, 2024 | Sell | RXRX | Michael Secora | Chief Financial Officer | 7,172 | $12.43 | $1.6B | -58.98% | +6.32% | $89.1K | -0.60% | — | Trim |
| Feb 15, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 11,148 | $12.43 | $1.6B | -58.98% | +6.32% | $138.6K | -1.00% | — | Trim |
| Feb 13, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 125,000 | $5.40 | $1.6B | -58.98% | +6.32% | $674.5K | +0.33% | 10b5-1 | Trim |
| Feb 9, 2024 | Sell | RXRX | David J Mauro | Chief Medical Officer | 1,892 | $10.09 | $1.6B | -58.98% | +6.32% | $19.1K | -0.30% | — | Trim |
| Feb 9, 2024 | Sell | RXRX | Michael Secora | Chief Financial Officer | 2,512 | $10.09 | $1.6B | -58.98% | +6.32% | $25.3K | -0.07% | — | Trim |
| Feb 9, 2024 | Sell | RXRX | Tina Marriott | President and COO | 2,800 | $10.09 | $1.6B | -58.98% | +6.32% | $28.3K | -0.15% | — | Trim |
| Feb 9, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 3,233 | $10.09 | $1.6B | -58.98% | +6.32% | $32.6K | -0.03% | — | Trim |
| Feb 7, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 89,522 | $5.84 | $1.6B | -58.98% | +6.32% | $522.5K | -0.58% | 10b5-1 | Trim |
| Jan 25, 2024 | Sell | RXRX | Tina Marriott Larson | President and COO | 16,000 | $5.70 | $1.6B | -58.98% | +6.32% | $91.2K | +0.00% | 10b5-1 | Trim |
| Jan 16, 2024 | Sell | RXRX | Shafique Virani | Chief Business Officer | 36,000 | $6.58 | $1.6B | -58.98% | +6.32% | $236.7K | +0.00% | 10b5-1 | Trim |
| Jan 16, 2024 | Buy | RXRX | Michael Secora | Chief Financial Officer | 125,000 | $5.47 | $1.6B | -58.98% | +6.32% | $684.0K | +0.49% | 10b5-1 | Trim |
| Jan 3, 2024 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 97,103 | $6.26 | $1.6B | -58.98% | +6.32% | $608.1K | -0.94% | 10b5-1 | Trim |
| Dec 28, 2023 | Sell | RXRX | Tina Marriott Larson | President and COO | 16,000 | $5.82 | $1.6B | -58.98% | +6.32% | $93.1K | +0.00% | 10b5-1 | Trim |
| Dec 15, 2023 | Sell | RXRX | Shafique Virani | Chief Business Officer | 36,000 | $5.91 | $1.6B | -58.98% | +6.32% | $212.8K | +0.00% | 10b5-1 | Trim |
| Dec 12, 2023 | Buy | RXRX | Michael Secora | Chief Financial Officer | 125,000 | $4.33 | $1.6B | -58.98% | +6.32% | $541.1K | +0.50% | 10b5-1 | Trim |
| Dec 6, 2023 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 101,079 | $5.20 | $1.6B | -58.98% | +6.32% | $525.9K | -0.80% | 10b5-1 | Trim |
| Nov 15, 2023 | Sell | RXRX | Tina Marriott Larson | President and COO | 11,378 | $5.46 | $1.6B | -58.98% | +6.32% | $62.1K | -0.27% | 10b5-1 | Trim |
| Nov 15, 2023 | Sell | RXRX | Shafique Virani | Chief Business Officer | 39,603 | $4.62 | $1.6B | -58.98% | +6.32% | $183.0K | -0.49% | 10b5-1 | Trim |
| Nov 14, 2023 | Buy | RXRX | Michael Secora | Chief Financial Officer | 132,172 | $4.23 | $1.6B | -58.98% | +6.32% | $558.9K | +0.26% | 10b5-1 | Trim |
| Nov 10, 2023 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 26,913 | $4.51 | $1.6B | -58.98% | +6.32% | $121.4K | -0.61% | 10b5-1 | Trim |
| Nov 1, 2023 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 93,427 | $4.27 | $1.6B | -58.98% | +6.32% | $398.8K | -0.33% | 10b5-1 | Trim |
| Oct 26, 2023 | Sell | RXRX | Tina Marriott Larson | President and COO | 6,000 | $3.34 | $1.6B | -58.98% | +6.32% | $20.1K | +0.00% | 10b5-1 | Trim |
| Oct 16, 2023 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 10,000 | $6.55 | $1.6B | -58.98% | +6.32% | $65.5K | -0.27% | 10b5-1 | Trim |
| Oct 16, 2023 | Sell | RXRX | Shafique Virani | Chief Business Officer | 36,000 | $4.26 | $1.6B | -58.98% | +6.32% | $153.4K | +0.00% | 10b5-1 | Trim |
| Oct 10, 2023 | Buy | RXRX | Michael Secora | Chief Financial Officer | 125,000 | $4.12 | $1.6B | -58.98% | +6.32% | $514.6K | +0.51% | 10b5-1 | Trim |
| Oct 4, 2023 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 91,044 | $5.59 | $1.6B | -58.98% | +6.32% | $508.5K | -0.27% | 10b5-1 | Trim |
| Sep 28, 2023 | Sell | RXRX | Tina Marriott Larson | President and COO | 6,000 | $4.39 | $1.6B | -58.98% | +6.32% | $26.3K | +0.00% | 10b5-1 | Trim |
| Sep 15, 2023 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 10,000 | $8.57 | $1.6B | -58.98% | +6.32% | $85.7K | -0.27% | 10b5-1 | Trim |
| Sep 15, 2023 | Sell | RXRX | Shafique Virani | Chief Business Officer | 36,000 | $5.44 | $1.6B | -58.98% | +6.32% | $195.8K | +0.00% | 10b5-1 | Trim |
| Sep 12, 2023 | Buy | RXRX | Michael Secora | Chief Financial Officer | 125,000 | $4.76 | $1.6B | -58.98% | +6.32% | $594.5K | +0.52% | 10b5-1 | Trim |
| Sep 6, 2023 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 90,015 | $6.61 | $1.6B | -58.98% | +6.32% | $594.9K | -0.29% | 10b5-1 | Trim |
| Aug 24, 2023 | Sell | RXRX | Tina Marriott Larson | President and COO | 6,000 | $4.86 | $1.6B | -58.98% | +6.32% | $29.1K | +0.00% | 10b5-1 | Trim |
| Aug 15, 2023 | Sell | RXRX | Tina Marriott Larson | President and COO | 5,378 | $9.18 | $1.6B | -58.98% | +6.32% | $49.4K | -1.27% | — | Trim |
| Aug 15, 2023 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 16,913 | $9.19 | $1.6B | -58.98% | +6.32% | $155.4K | -1.90% | — | Trim |
| Aug 15, 2023 | Sell | RXRX | Shafique Virani | Chief Business Officer | 39,603 | $6.05 | $1.6B | -58.98% | +6.32% | $239.6K | -0.49% | 10b5-1 | Trim |
| Aug 15, 2023 | Buy | RXRX | Michael Secora | Chief Financial Officer | 129,727 | $5.12 | $1.6B | -58.98% | +6.32% | $664.3K | +0.37% | 10b5-1 | Trim |
| Aug 9, 2023 | Sell | RXRX | Christopher Gibson | Chief Executive Officer | 10,000 | $10.97 | $1.6B | -58.98% | +6.32% | $109.7K | -0.26% | 10b5-1 | Trim |